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TABLE 1. Outcomes, Week 152
GmTSS TCZ8 n¼ 244 TCZ4 n¼ 241 Control n¼219
Mean (S.D.) change from BL 0.72 (2.56)*,y 0.71 (2.14)y,z 1.78 (3.64)
Pts with no progression
(GmTSS change from
BL 0), % (n)
69 (169)*,x 67 (162)x,k 51 (111)
Signs and Symptoms All TCZ
ACR20, % (n/n) 80 (472/591)
ACR50, % (n/n) 59 (346/591)
ACR70, % (n/n) 36 (212/591)
DAS28 remission, % (n/n) 57 (325/572)
TJC and SJC¼ 0, % (n/n) 21 (137/656)
HAQ<0.5 % (n/n) 37 (202/552)
n/n: no. patients achieving end point/no. patients reaching timepoint with valid
assessments. *p< 0.0001 vs control. yp calculated by Van Elteren test stratified by
region. zp¼ 0.0002 vs PBO. xp calculated by logistic regression analysis adjusted
for region. kp¼ 0.0008 vs control.
222. PEPTIDYLARGININE DEIMINASE FROM
PORPHYROMONAS GINGIVALIS AS A POTENTIAL
TARGET FOR THE TREATMENT AND PREVENTION OF
RHEUMATOID ARTHRITIS
Natalia Wegner1, Helena Lugli1, Anne-Marie Quirke1, Yonghua Guo2,
Jan Potempa2,3 and Patrick Venables1
1The Kennedy Institute of Rheumatology, Imperial College, London,
United Kingdom; 2School of Dentistry, Oral Health and Systemic
Disease, University of Louisville, Louisville, KY, USA; 3Department of
Microbiology, Jagiellonian University, Krakow, Poland
Background: Porphyromonas gingivalis (P. gingivalis) is a major
bacterium in the pathogenesis of periodontitis. Several epidemiologi-
cal studies have shown an association between periodontitis and
rheumatoid arthritis (RA). We demonstrated cross-reactivity between
citrullinated human a-enolase and P. gingivalis enolase, and that the
anti-citrullinated a-enolase response links with DR4 alleles and
smoking, common susceptibility factors for RA and periodontitis.
Recently, we reported that P. gingivalis peptidylarginine deiminase
(PPAD) catalyses the citrullination of carboxy-terminal arginines to
citrulline, in both bacterial and human peptides. Bacterial citrullination
might therefore be aetiologically important in a subset of RA by driving
the autoimmune response to citrullinated proteins. Hence, we
investigated the PPAD enzyme as a potential new therapeutic target.
Methods: Recombinant full-length PPAD was expressed in E. coli,
purified, and tested for enzymatic activity. A specific antibody to PPAD
was developed by immunising rabbits with recombinant protein. The
subcellular localisation of PPAD was investigated by fractionation of
P. gingivalis and blotting with anti-PPAD antibody. Cross-reactivity
with human PADs was examined by western blot. PPAD inhibition
studies were performed using tetracycline, doxycycline, minocycline,
sulfasalazine, methotrexate, and 2-chloroacetamidine. Site-directed
mutagenesis was performed to investigate the contribution of a
conserved cysteine residue to enzyme activity.
Results: Full-length PPAD was active and citrullinated a-enolase and
fibrinogen peptides harbouring carboxy-terminal arginines, but not
peptides with internal arginines. Blotting of subcellular fractions with
a PPAD-specific antibody demonstrated that the enzyme is located
on the cell surface of various P. gingivalis strains. Anti-PPAD antibody
did not cross-react with human PADs. 2-chloroacetamidine proved
an effective inhibitor with half-maximal inhibition (IC50) at 25M.
Tetracycline, doxycycline, minocycline, sulfasalazine or methotrexate
did not inhibit PPAD activity. The substitution of cysteine-351 with
alanine completely abolished PPAD activity.
Conclusions: The cell-surface localisation identifies PPAD as a
putative virulence factor and suitable pharmaceutical target.
Cysteine-351 as a crucial catalytic residue indicates that agents
targeting cysteines can be effective inhibitors. This is confirmed by the
inhibitory activity of 2-chloroacetamidine in the low M-range. Our
combined results suggest that PPAD and human PADs have different
three-dimensional structures but share a similar, although not
identical, catalytic mechanism. Our findings form the basis for further
characterisation, such as crystallisation and the development of more
potent and specific inhibitors with the potential to prevent RA by
inhibiting the generation of the autoantigens which drive the disease.
Disclosure statement: The authors have declared no conflicts of
interest.
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223. LONG TERM OUTCOME IN A CONTEMPORARY
SYSTEMIC SCLEROSIS COHORT
Svetlana Nihtyanova1, Voon Ong1, Carol Black1 and Chris Denton1
1Centre for Rheumatology and Connective Tissue Diseases,
Royal Free Hospital, London, United Kingdom
Background: We have previously compared outcome in two groups of
systemic sclerosis (SSc) patients with disease onset a decade apart
and we reported data on 5 year survival and cumulative incidence of
organ disease in a contemporary SSc cohort. The present study
examines longer term outcome in an additional cohort of SSc followed
for 10 years.
Methods: We have examined patients with disease onset between
years 1995 and 1999 allowing for at least 10 years of follow-up in a
group that has characteristics representative for the patients we see in
contemporary clinical practice.
Results: Of the 398 patients included in the study, 252 (63.3%) had
limited cutaneous (lc) SSc and 146 (36.7%) had diffuse cutaneous (dc)
SSc. The proportion of male patients was higher among the dcSSc
group (17.1% v 9.9%, p¼ 0.037) while the mean age of onset was
significantly higher among lcSSc patients (50 13 v 4613
yearsSD, p¼0.003).
During a 10 year follow-up from disease onset, 45% of the dcSSc
and 21% of the lcSSc subjects developed clinically significant
pulmonary fibrosis, p<0.001. Among them approximately half
reached the endpoint within the first 3 years (23% of dcSSc and
10% of lcSSc) and over three quarters within the first 5 years (34% and
16% respectively). There was a similar incidence of pulmonary
hypertension (PH) in the two subsets with a steady rate of increase
over time. At 10 years 13% of dcSSc and 15% of lcSSc subjects had
developed PH (p¼0.558), with the earliest cases observed within the
first 2 years of disease. Comparison between subjects who developed
PH in the first and second 5 years from disease onset demonstrated
no difference in demographic or clinical characteristics, but 5-year
survival from PH onset was better among those who developed this
complication later in their disease (49% v 24%), with a strong trend
towards statistical significance (p¼0.058). Incidence of SSc renal
crisis (SRC) was significantly higher among the dcSSc patients (12% v
4% in lcSSc, p¼0.002). As previously observed, the rate of
development of SRC was highest in the first 3 years of disease-
10% in dcSSc and 3% in lcSSc. All incidences of clinically important
cardiac disease developed in the first 5 years from disease onset
(7% in dcSSc v 1% in lcSSc, p< 0.001) and remained unchanged at
10 years. As expected, 10-year survival among lcSSc subjects
was significantly higher (81%) compared to that of dcSSc patients
(70%, p¼0.006). Interestingly, although over the first 5 years the death
rate was much higher in the dcSSc cohort (16% v 6% in lcSSc), over
the following years it became very similar for both subsets (14% and
13% between years 5 and 10, and 18% and 17% between years 10
and 15 for dcSSc and lcSSc respectively).
Conclusions: Even though dcSSc patients have higher incidence for
most organ complications compared to lcSSc subjects, the worse
survival among them is mainly due to higher early mortality rate.
Mortality rate after first 5 years of disease becomes comparable in
the two disease subsets.
Disclosure statement: The authors have declared no conflicts of
interest.
224. SYSTEMIC SCLEROSIS MANAGEMENT: ARE WE
DOING AS WELL AS WE COULD?
Pamela Lutalo1, Warren Shattles1, Hugh Jones2, Reem Nouri3,
Alastair Hepburn4, Michael Chard4, Natalie Horwood5, Myo Lynn6,
Oliver Duke7, Patrick Kiely6, Louisa Zouita8, Ursula Davies1,
Rod Hughes3 and Mark Lloyd9
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2Rheumatology, Kingston Hospital, Kingston, United Kingdom;
3Rheumatology, St Peter’s Hospital, Chertsey, United Kingdom;
4Rheumatology, Western Sussex Hospitals, Worthing,
United Kingdom; 5Rheumatology, Mayday Hospital, Thornton Heath,
United Kingdom; 6Rheumatology, St George’s Hospital, London,
United Kingdom; 7Rheumatology, St Helier Hospital, Carshalton,
United Kingdom; 8Audit, Frimley Park Hospital, Frimley,
United Kingdom; 9Rheumatology, Frimley Park Hospital, Frimley,
United Kingdom
Background: 2009 EULAR guidelines set clear standards for the
treatment of systemic sclerosis (SSc). We wanted to assess our
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management against these standards, and to look at our general
management of SSc.
Methods: The audit was conducted within the South West Thames
Regional Audit Group. All members were invited to participate by
identifying SSc patients and submitting data via a proforma.
Results: Data on 83 patients from 9 hospitals was received. 82% were
female; mean age 61yr (23-89). Commonest autoantibody status is
shown in Table 1. Skin: 17 patients required immunosuppressant
drugs for skin disease: MMF (8), MTX (7) (mean dose 15 mg/wk), AZA
(2). Only 1 patient had an adequately documented skin score. Digital
vasculopathy: 46 patients had Raynaud’s phenomenon or digital
ulceration requiring treatment: 28 were on 1st line therapy (Ca
antagonists),17 on 2nd line therapy (iloprost or epoprostenol), 1 on
3rd line therapy (bosentan). Lung: 17 patients had CT evidence of
interstitial lung disease (ILD). 6 patients were on present treatment:
cyclophosphamide (2), MMF (2) steroids (2). 12/17 patients with ILD
and only 42/83 total patients had annual lung function tests. Pulmonary
hypertension (PAH): 18 patients were classified as having mild PAH
(mean PAP 20-51 mmHg),6 as moderate (mean PAP 23-45 mmHg), 1
as severe (mean PAP 39 mmHg on treatment). WHO severity
classification was only available in 13 patients (9¼ I, 1¼ II, 3¼ III).
Current treatment included diuretics (6), bosentan (3),sildenafil (2),
epoprostenol (2). 3 were on home oxygen. All patients with PAH but
only 54 (65%) of all patients in the audit were undergoing annual echo.
BP: Only 52 (63%) had BP check each clinic visit. 58 patients had a
current recorded BP and of these patients 13 were hypertensive
(SBP>140 mmHg or DBP>90 mmHg). Anti-hypertensive treatment
included ACE-I (25), Angiotensin II RA (19) and others (15). Renal: 16
patients had eGFR<60 ml/min (lowest 22 ml/min). 5 patients had
suffered SSc renal crisis. Digestive tract: 44 (53%) had oesophageal
involvement; 14 (17%) had bowel involvement. 37 were on a PPI, 2 on
pro-kinetics and 2 on rotating antibiotics. None were having NG or
PEG feeding. 14 patients were current steroid users (commonest
indication: joint pain (6 patients)); 12/14 had BP check every visit.
Conclusions: This audit shows the importance of regional networks in
gathering adequate patient numbers in rare rheumatic conditions. Our
SSc drug management appears to accord well with EULAR guidance.
However, there is room for improvement in our monitoring of skin
scores, blood pressure, lung function, echocardiography and PAH
functional status.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1. Auto-antibody status (% of patients)
ANA 96
Centromere 43
Scl-70 34
Ro 6
U1 RNP 4
RNA I,II, III 1
225. CYTOKINES AND GROWTH FACTORS RELEASED
INTO CONDITIONED MEDIA BY EPIDERMAL AND DERMAL
EXPLANTS OF HEALTHY CONTROLS AND SYSTEMIC
SCLEROSIS PATIENTS
Joanna Nikitorowicz Buniak1, Xu Shiwen1, David Abraham1,
Chris Denton1, Carol Black1 and Richard Stratton1
1Centre for Rheumatology and Connective Tissue Diseases, UCL,
London, United Kingdom
Background: Systemic sclerosis (SSc) epidermal cells show signs of
injury and activation similar to changes observed during the wound
healing process. Keratinocytes secrete chemo-attracting agents and
growth factors influencing the phenotype and proliferation rate of
fibroblasts. We hypothesized that in SSc injured epidermal cells
release chemokines and cytokines capable of recruiting immune cells
to the skin and promoting fibrosis. We decided to determine the array
of cytokines and growth factors released by SSc epidermal and dermal
cells.
Methods: In the preliminary study 4 mm forearm biopsies were taken
from 6 healthy controls and 6 SSc patients with various stage and type
of disease. Dermis and epidermis were separated using trypsin/EDTA
and incubated overnight with 1 ml of serum free media. Then the media
were collected and analysed using LegendPLEX/ELISA for presence of
CCL20, HGF, G-CSF, GM-CSF, VEGF, PDGF-AA, PDGF-BB, MCP-1,
FGF-2, IL-8, IL-1a, IL-1b and IL-1ra. The statistical analysis was
performed using Wilcoxon rank-sum test.
Results: Predominant amongst growth factors released by the
epidermal explants were chemokines MCP-1 and IL-8 (Table 1). A
trend towards increased IL-8 release by SSc epidermis comparing to
control epidermis was observed, similar with MCP-1. Also HGF was
abundantly present in both epidermis and dermis with trend towards
significant increase in the SSc dermis. Moreover, elevated levels of
IL-1ra were detected in SSc dermis when matched to controls. VEGF
was produced in higher amounts by SSc dermis.
Conclusions: Growth factors and cytokines released by SSc explants
can be assessed using Luminex cytokine arrays. Chemokines IL-8
and MCP-1 predominate in the conditioned media from epidermal
biopsies, whereas HGF and MCP-1 release was prominent in the
dermal. The epidermis is confirmed as a possible source of chemo-
kines in SSc. Our further work will focus on possibility to categorise
SSc patients based on cytokine profiling arrays of explant skin biopsy
material.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1. Mean and standard error of the mean (SEM) concentration of growth
factors and cytokines in the conditioned media.
Growth
factor
Control
epidermis
SSc
epidermis
Control
dermis
SSc dermis
Mean SEM Mean SEM Mean SEM Mean SEM
CCL20 5.03 8.899 1.43 6.737 13.72 9.141 2.92 1.849
HGF 549.64 49.110 805.62 167.069 800.89 85.991 795.87 224.324
G-CSF 56.32 19.787 24.16 7.004 62.97 35.173 9.01 2.826
GM-CSF 0.00 0.00 0.00 0.00 0.20 0.197 0.00 0.00
VEGF 75.33 30.382 88.11 27.514 23.93 4.806 35.12 11.531
PDGF-AA 1.04 0.488 3.35 1.285 3.49 1.190 4.35 1.987
PDGF-BB 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MCP-1 846.14 372.356 810.40 452.211 2258.44 1194.114 422.12 222.845
FGF-2 0.35 0.348 0.43 0.303 0.90 0.446 0.66 0.273
IL-8 828.95 278.716 1335.83 504.504 1721.21 882.055 714.10 138.508
IL-1a 46.56 25.935 19.36 5.564 1.54 0.995 0.99 0.746
IL-1b 0.39 0.237 0.47 0.147 0.26 0.151 0.17 0.075
IL-1ra 110.33 81.088 40.82 17.946 2.07 1.792 7.19 0.075
226. LATE ONSET SYSTEMIC SCLEROSIS: A SYSTEMATIC
SURVEY OF THE EULAR SCLERODERMA TRIALS AND
RESEARCH GROUP DATABASE
Thomas Hu¨gle1,2, Philipp Schuetz3, Thomas Daikeler2, Alan Tyndall2,
Marco Matucci-Cerinic4, Ulrich A. Walker2 and Jacob M. van Laar1
1Muskuloskeletal Research Group, University of Newcastle,
Newcastle upon Tyne, United Kingdom; 2Department of
Rheumatology, Basel University, Basel, Switzerland; 3School of
Public Health, Harvard School of Medicine, Boston, MA, USA;
4Division of Rheumatology, Department of Biomedicine, AOUC,
Denothe Centre, University of Florence, Florence, Italy
Background: The clinical course of SSc depends on subtype, organ
involvement and age. Few data are reported on patients suffering from
late-onset SSc.
Methods: We analysed data from 8554 patients prospectively
followed in the EULAR Scleroderma Trials and Research (EUSTAR)
group database. Late-onset SSc was defined as onset of non-RP
disease features at or beyond 75 years of age. Disease characteristics,
clinical features, disease course and mortality were evaluated.
Results: A total of 123 patients with SSc onset at or beyond 75 years
of age were identified. Compared with patients <75 years they had
more frequently limited than diffuse SSc and a higher prevalence of
anti-centromere autoantibodies. Fewer old patients had digital ulcers.
The modified Rodnan’s skin score, the prevalence of lung fibrosis and
renal crisis did not differ significantly between groups. Pulmonary
hypertension (PH) measured by echocardiography was more prevalent
in the late-onset group, as well as arterial hypertension and diastolic
dysfunction. Late-onset SSc remained a positive predictor for PH in
multivariate analyses. No significant difference of the two groups in
skin score or diffusion capacity was observed during follow-up.
Mortality due to SSc was higher in the late-onset group, but the
survival time from diagnosis was longer compared with the younger
patients.
Conclusions: Late-onset SSc shows a distinct clinical presentation
and outcome. Patients with late-onset SSc suffer more frequently from
the limited subtype and PH, but fewer patients have digital ulcers.
PH may in part be determined by underlying cardiovascular disease.
Disclosure statement: The authors have declared no conflicts of
interest.
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227. INFLUENCE OF THE COLD CHALLENGE ON THE
DISCRIMINATORY CAPACITY OF THE DIGITAL
DISTAL-DORSAL THERMAL GRADIENT IN THE
THERMOGRAPHIC ASSESSMENT OF RAYNAUD’S
PHENOMENON
John D. Pauling1, Victoria Flower1 and Neil McHugh1,2
1Rheumatology, Royal National Hopsital for Rheumatic Disease,
Bath, United Kingdom; 2School for Pharmacy and Pharmacology,
University of Bath, Bath, United Kingdom
Background: A key challenge facing clinicians evaluating patients
with Raynaud’s phenomenon (RP) is the early identification of those
patients at risk of connective tissue disease such as systemic sclerosis
(SSc), in whom RP can predate the onset of other clinical manifesta-
tions by many years. This study evaluates the influence of the cold
challenge on the discriminatory capacity of the digital longitudinal
thermal gradient in differentiating between primary RP and SSc.
Methods: A retrospective review was performed of unselected
patients with primary RP (n¼27) and SSc (n¼ 28) in whom thermo-
graphic assessment of RP had been undertaken. The ‘distal-dorsal
difference’ (DDD) for each digit (and a composite score of all fingers)
was calculated at baseline and 10 minutes following standardised cold
challenge (60s at 208C). The discriminatory capacity of the mean DDD
for individual digits, and the composite score of all fingers, before and
after cold exposure was assessed.
Results: There was significant variation in the DDD for each digit in
both groups (Table 1). The mean DDD of the thumbs was significantly
higher than the digits in both PRP (P< 0.05) and SSc (P< 0.005). The
fingers provided greater discriminatory capacity between patient
groups than the thumbs at baseline, although the associations only
achieved borderline significance owing to the large variation of the
data (Table 1). The cold challenge led to signifcant increases in the
magnitude of the DDD for all digits in primary RP, but not in SSc. This
reduced the discriminatory capacity of the DDD after cold challenge by
narrowing differences present between RP subgroups at baseline.
The composite score of all fingers failed to improve the overall
discriminatory capacity of the mean DDD (P¼ 0.11).
Conclusions: Large variation in the DDD amongst patients prevents
easy discrimination between disease states although the fingers
appear to provide greater discriminatory capacity than the thumbs.
Relative sparing of the thumb occurs in both primary RP and SSc but
this does not aid differentiation between disease states. Our findings
question the value of the cold challenge in the thermographic
assessment of RP and its contribution must be reappraised.
Baseline assessment alone, if sufficient, may facilitate greater use of
thermographic assessment of RP outside that of specialist centres.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1. DDD for individual digits and a composite score of all digits, before
and after cold challenge
Primary RP
(n¼ 27) Mean (S.D.)
Baseline Post CST
SSc (n¼ 28)
Mean (S.D.)
Baseline Post CST
Primary RP vs SSc
P value Baseline
Post CST
Thumb 1.0 (2.6) 1.7 (2.0)* 1.4 (2.5) 1.8 (3.1) 0.51 0.95
Index 1.4 (2.7) 2.7 (3.1)* 2.7 (2.6) 3.2 (3.1) 0.08 0.55
Middle 1.9 (2.7) 3.1 (2.9)* 2.9 (2.5) 3.4 (3.0) 0.18 0.67
Ring 1.9 (2.7) 3.2 (3.1)* 3.2 (2.4) 4.0 (2.8)* 0.07 0.34
Little 1.9 (2.7) 3.3 (3.0)* 3.2 (2.6) 4.0 (3.0)* 0.06 0.39
Composite
of all digits
1.62 (2.6) 2.81 (2.9)* 2.7 (2.2) 3.28 (2.8) 0.11 0.54
RP: Raynaud’s phenomenon; SSc: systemic sclerosis; CST: cold stress test.
*p<0.05 for baseline vs post CST.
228. CTGF/CCN2 IS ESSENTIAL FOR SKIN SCLERODERMA
Shangxi Liu1 and Andrew Leask1
1Dentistry, University of Western Ontario, London, ON, Canada
Background: Connective tissue growth factor (CTGF/CCN2) is highly
overexpressed in fibrotic disease including in scleroderma (systemic
sclerosis/SSc. In fact, CTGF/CCN2 is a good surrogate marker for the
severity of the fibrosis in this disease. However, whether CTGF/CCN2
expression functionally contributes to the fibrosis in SSc is not fully
understood. The critical cell type contributing to the fibrosis in SSc is
considered to be the myofibroblast. The aim of this study was to
determine whether CTGF/CCN2 is required for the development of
skin scleroderma and whether CTGF/CCN2 is required for myofibro-
blast differentiation or recruitment.
Methods: We subjected control mice or mice deleted for CTGF/CCN2
in fibroblasts to the bleomycin-induced model of skin SSc. The extent
of fibrosis was assessed histologically using hematoxylin and eosin
staining. The appearance of myofibroblasts was assessed using anti-
a-smooth muscle actin antibodies. Collagen deposition was assessed
using hydroxproline/proline analysis and trichrome staining. Fibroblast
responses to TGFbeta were assessed using real time PCR to detect
mRNA expression. Whether pericytes were induced into the fibrotic
lesion was assessed using an antibody against NG2.
Results: Loss of CTGF/CCN2 resulted in resistance to bleomycin
induced skin fibrosis; compared to controls, loss of CTGF/CCN2
resulted in resistance to bleomycin-induced skin thickness and
collagen deposition (all N¼6, all p< 0.01). TGFbeta was able to
induce collagen and a-SMA mRNA expression in CTGF/CCN2 knock-
out cells (N¼6; p< 0.05). In wild type mice, bleomycin caused the
appearance of a-SMA expressing myofibroblast that were also
positive for the pericyte marker NG2; whereas, in mice lacking
CTGF/CCN2, a-SMA/NG2-expressing myofibroblasts were not
recruited into the fibrotic lesion (N¼ 6, p<0.01).
Conclusions: CTGF/CCN2 is required for bleomycin-induced skin
scleroderma. CTGF/CCN2, as it is required for myofibroblasts/pericyte
recruitment, could be a good target for antifibrotic drug intervention
in SSc.
Disclosure statement: A.L. is a shareholder of FibroGen. All other
authors have declared no conflicts of interest.
229. ANALYSIS OF SIGNAL TRANSDUCTION IN SYSTEMIC
SCLEROSIS EPIDERMIS
Joanna Nikitorowicz Buniak1, Nima Aden1, Chris Denton1,
David Abraham1 and Richard Stratton1
1Centre for Rheumatology and Connective Tissue Diseases,
Royal Free Hospital UCL, London, United Kingdom
Background: Systemic sclerosis (SSc) is a severe disease charac-
terised by cellular injury and activation in early stage, followed by
autoimmunity and fibrosis. Previously, we found using a proteomic
analysis of diffuse SSc and healthy control forearm skin biopsy
material, activation of the disease epidermis. Therefore, we decided to
look at the signalling pathways that might be responsible for the state
of activation, and as a result lead to fibrosis.
Methods: Epidermal biopsies from early diffuse patients and healthy
controls (both n¼4) were lysed for phosphorylation array analysis
(Kinexus). The arrays included 880 proteins associated with diverse
processes. The data were compared using permutation analysis
software SAM for Excel. In addition further biopsies from both patients
and controls (both n¼6) were studied by immunohistochemistry for
proteins identified in the array analysis as altered in phosphorylation
status (phospho-smad 2/3, p-38a, c-Met and c-jun).
Results: The array analysis indicated increase in phosphorylation
status of proteins responsible for response to stress, wound healing as
well as histone modifications, in the disease (Table 1). Immunohisto-
chemistry revealed elevated phospho-p38a and phospho-c-jun in
basal layer keratinocytes in SSc. Smad2/3 phosphorylation was seen
throughout the SSc epidermis and in cells in the adjacent upper
dermis. C-Met phosphorylation was seen in cytoplasm of SSc
epidermis at all levels of differentiation.
Conclusions: The activated phenotype of SSc keratinocytes may
be initiated by environment induced stress signaling in basal layer
keratinocytes (MAPKs p38 and c-jun),or be maintained by HGF
released by underlying mesenchymal cells (c-Met signaling). Cells in
the upper dermis are being induced via SMAD signaling pathway and
should be further characterized to distinguish epithelial-mesenchyme
transition vs induction of adjacent fibroblasts. The altered differentia-
tion in SSc epidermis may involve epigenetic histone modification.
Disclosure statement: The authors have declared no conflicts of
interest.
230. IDENTIFICATION OF POTENTIAL MARKERS OF SKIN
FIBROSIS USING TARGETED DISRUPTION OF TGF BETA
SIGNALING IN TRANSGENIC MICE
Korsa Khan1, Rachel Hoyles1, Xu Shiwen1, Voon Ong1,
David Abraham1 and Chris Denton1
1Centre for Rheumatology and Connective Tissue Diseases,
UCL Medical School, London, United Kingdom
Background: TGFb is a profibrotic cytokine involved in tissue repair
and wound healing. We have demonstrated that deletion of TbRII
selectively in fibroblasts is antifibrotic. Previous studies show that mice
from this strain are highly resistant to bleomycin induced experimental
fibrosis. We have used this model to identify potential key mediators of
fibrotic scar formation in the skin. These may include novel markers
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that could be used to assess disease activity in systemic sclerosis
(SSc).
Methods: We have deleted TbRII in fibroblasts of mice post-natally,
using a Cre-Lox strategy that circumvents the embryonic lethality of a
conventional knock-out for this gene by the administration of
tamoxifen to activate Cre recombinase and hence deletion of TbRII.
Gender matched littermates were studied and 4 mm dermal punch
wounds performed. Wound histology was assessed for collagen
deposition using Sirius red and Masson’s trichrome stains. Dermal
fibroblasts cultured from wildtype or mutant mice were treated with
recombinant TGFb1 (2 ng/ml) and illumina microarray gene profiling
performed.
Results: Healing of full thickness skin wounds was severely impaired
in mice after fibroblast-specific deletion of TbRII. For wildtype wounds
at 14 days mean ( sd) diameter was 0.57 mm ( 0.29) compared with
1.75 mm (0.28) for TbRII-null-fib wounds (p¼0.001). In 7 day null
wounds there was reduced expression of markers of wound healing
including alpha-SMA. Illumina microarray analysis defined a TGFbeta
induced gene cohort in wildtype cells and confirmed that mutant
fibroblasts were essentially refractory. Key marker genes for
myofibroblast phenotype were not induced and induction of several
candidate profibrotic mediators including CTGF and endothelin-1 was
diminished. Representative data for 5 key genes is summarised in
Table 1.
Conclusions: Our findings confirm that an intact TGFbeta response in
resident dermal fibroblasts plays a key role in normal skin wound
healing. Our observations are potentially relevant to strategies that
aim to attenuate fibrosis since these same approaches may have
detrimental effects on connective tissue repair. This mouse strain
provides a platform for better understanding human fibrotic disease
such as SSc and genes that show differential expression may be
candidate markers of scar formation and fibrosis.
Disclosure statement: The authors have declared no conflicts of
interest.
231. HAEMOGLOBIN VIDEO IMAGING OF CONJUNCTIVAL
MICROCIRCULATIONS IN SYSTEMIC SCLEROSIS
Shweta Bhagat1, Tom Drummond2, Cyndi Goh3, Robert Busch4,
Frances Hall4 and Paul Meyer5
1Rheumatology Research Unit, Addenbrooke’s Hospital, Cambridge,
United Kingdom; 2Department of Engineering, University of
Cambridge, Cambridge, United Kingdom; 3Rheumatology,
Addenbrooke’s Hospital, Cambridge, United Kingdom; 4School of
Clinical Medicine, University of Cambridge, Cambridge,
United Kingdom; 5Department of Ophthalmology, Addenbrooke’s
Hospital, Cambridge, United Kingdom
Background: Haemoglobin video imaging (HVI) of the conjunctiva and
episclera enables erythrocytes to be visualized at high resolution within
vessel lumina. This presents the opportunity of investigating micro-
circulatory disease non-invasively and in real time. Systemic sclerosis
(SSc) was studied as a model system due to the characteristic arterial
microvasculopathy which leads to vessel occlusion and progressive
tissue ischaemia.
Objective: To devise a nomenclature to describe the architecture of
the conjunctival microcirculatory lobules.
To extract an initial metric by which to compare lobular architecture
in patients and SSc controls.
Methods: HVI documents erythrocyte flow by illuminating the
microcirculation with green light, absorbed by haemoglobin, and
recording its reflection from the underlying sclera using a digital video
camera (1360 x 1024 pixels). Software was developed to stabilise the
image motion resulting from micro-saccades. Recordings from a 5 x
3.7mm region adjacent to the corneo-scleral limbus were captured at
30 frames /sec over 1 minute in 12 healthy controls and 12 patients
with SSc. A nomenclature was developed for the microcirculation, in
which each vessel segment between branch-points was assigned a
number to denote its relative position in a circulatory lobule. For each
lobule, the vessel segment distal to the final bifurcation and proximal to
the first convergence was designated ‘‘0’’. Proximal (arterial) vessel
segments were assigned ‘‘-1’’, ‘‘-2’’ etc and distal (venous) vessels
‘‘þ1’’, ‘‘þ2’’ etc. The mean vessel segment assignment (MVSA) for
each segment was the mean of the assignments for all the lobules in
which it participated. Software was developed to semi-automate the
assignment and data output. The effect of arterial dropout on the
MVSA was modelled according to whether the vessels downstream of
the dropout are resorbed (MVSA unchanged) or resupplied by
connection with an adjacent lobule, and, if resupplied, whether the
connection is at a level equivalent (MVSA unchanged), above (MVSA
reduced) or below (MVSA increased) that of the lost arterial segment.
TABLE 1.
Biologic
process
Protein Fold increase
in SSc
P value Function
Stress/injury
response
Jun proto-oncogene-encoded AP1 transcription factor
(c-jun)
2.37 0.02 AP-1 transcription factor downstreram of C-jun N-terminal
kinase stress activated MAPK
Dual specificity protein kinase 2.18 0.019 Regulator of MAPKs
Mitogen activated protein- serine kinase p38a (T180 Y182) 2.13 0.05 Stress-induced MAPK
Mitogen-activated protein-serine kinase p38a (pan
specific)
1.53 0.014 Stress-induced MAPK
MAPK/ERK protein-serine kinase 2 (MKK2) 1.73 0.029 Response to extracellular growth factors
Tank-binding protein-1 1.55 0.039 type I interferon pathway/TLR3 signalling
MAPK/ERK protein-serine kinase 1 (MKK1) 1.48 0.039 Response to extracellular growth factors
Inhibitor of NF-kappa-B alpha (MAD3) 1.35 0.019 Regulation of NFB pathway
NF-kappa-B p65 nuclear transcription factor 1.23 0.046 Forms heterodimer with NF-B transcription factor.
Required for nuclear translocation of NF-B
Regulation of
tissue repair
Hepatocyte growth factor (HGF) receptor (c-Met) 2.89 0.05 Mesenchymal-epithelial signalling
STAT3 2.18 0.05 Signalling downstream of c-Met, IL-6 or other inflamma-
tory cytokine
STAT2 1.62 0.015
Integrin-linked protein-serine kinase 1 2.17 0.04 Coupling of signal transduciton to adhesion and motility
during wound repair
PDGF receptor kinase a 1.75 0.017 PDGF receptor signal transduction
PDGF receptor kinase a/b 1.63 0.036 PDGF receptor signal transduction
SMAD2 1.64 0.029 TGFb dependent signal transduction
Epigenetic
silencing
Protein-serine phosphatase 4-regulatory subunit (PPX/A’2) 2.57 0.00052 Regulator of histone deacetylase
TABLE 1. Normalised gene expression in skin fibroblasts from wildtype and mutant mice
WILDTYPE (N¼6) NULL (N¼4)
GENE BASAL TGFb1 BASAL TGFb1
Mean S.D. Mean S.D. Fold Change P Value Mean S.D. Mean S.D. Fold Change P Value
alphaSMA 2260 1329 9363 3176 4.1 0.00009 3136 707 962 1220 1.1 0.23
Transgelin 1231 870 4748 1267 3.9 0.00005 1505 564 518 695 1.2 0.20
Endothelin-1 352 108 1115 304 3.2 0.00002 356 79 109 71 1.1 0.21
Myosin Heavy
Chain
324 221 985 642 3.0 0.01021 408 93 126 108 1.1 0.18
CTGF 5783 3196 12198 5210 2.1 0.01014 4352 3006 1840 4426 1.1 0.11
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Results: The mean and 95% confidence intervals were calculated for
MVSAs arising from arterial segment levels in healthy controls. Of the
12 SSc patients, 9 had arterial MVSAs within the normal range. Three
patients each had a series of arterial segments for which MVSAs fell
below this range.
Conclusions: These data have provided a first metric by which to
analyse remodeling in a multi-level living human microcirculation. They
are consistent with arterial dropout and anastomosis between
adjacent lobules at the zero order level. This pilot study indicates
that HVI offers potential for non-invasive imaging of the microcircula-
tion in SSc and other diseases characterized by microvascular
pathology.
Disclosure statement: The authors have declared no conflicts of
interest.
232. ELEVATED MMP-7 SERUM LEVELS AS MARKER FOR
TISSUE REMODELLING AND FIBROSIS IN SYSTEMIC
SCLEROSIS AS A MODEL DISEASE
Pia Moinzadeh1, Thomas Krieg1, Martin Hellmich2,
Juergen Brinckmann3, Elena Neumann4, Ulf Mueller-Ladner4,
Alexander Kreuter5, Daniel Dumitresco6, Stefan Rosenkranz6 and
Nicolas Hunzelmann1
1Department of Dermatology, University of Cologne, Cologne,
Germany; 2Institute of Medical Statistics, Informatics and
Epidemiology, University of Cologne, Cologne, Germany;
3Department of Dermatology, University of Luebeck, Luebeck,
Germany; 4Department of Rheumatology, University of Giessen,
Giessen, Germany; 5Department of Dermatology, University of
Bochum, Bochum, Germany; 6Department of Cardiology, University
of Cologne, Cologne, Germany
Background: Fibrosis is characterized by an excessive accumulation
of connective tissue due to a disturbed balance between synthesis and
degradation of extracellular matrix proteins (ECM). This is regulated by
matrix metalloproteinases (MMPs) and their inhibitors (TIMPs).
Matrix Metalloproteinase-7 is involved in the degradation of ECM in
many physiological situations as well as in other disease processes,
like tumor invasion, wound healing and lung fibrosis. It was the aim of
the present study to investigate whether serum MMP-7 levels might
reflect the tissue remodeling going on during the course of fibrotic
diseases, using systemic sclerosis (SSc) a prototypic fibrotic disease
as a model.
Methods: Serum samples were obtained from 123 patients with
systemic sclerosis. MMP-serum levels of all SSc patients were
compared with age matched healthy controls (n¼22) that had no
rheumatic disease by using a commercial enzyme immunoassay kit
(Quantikine).
Results: An increased median serum MMP-7 level of 5.15 ng/ml
was found in scleroderma patients when compared to controls
(p<0.0001). Male patients showed a significant higher level of
MMP-7 compared to female patients (p¼ 0.016) and patients suffering
from the limited form of SSc (lSSc) showed lower MMP-7 serum levels
compared to the diffuse form (dSSc), but their differences did not
reach significance (p¼ 0.064). Diffuse type of scleroderma patients
were more frequently male (26%), and suffered more frequently from
PAH (22%), lung fibrosis (57%), kidney failure (24%) and heart
involvement (14%), when compared to patients with the limited form
of SSc. Median MMP-7 serum levels were significantly different
between patients with or without lung fibrosis (5.98 ng/ml versus
4.17 ng/ml; p<0.016). Accordingly, patients with dyspnea also had
significantly higher MMP-serum levels (p¼ 0.024). SSc patients
suffering from lung fibrosis without combined PH had lower mean
MMP-7 serum levels compared to SSc patients suffering from lung
fibrosis with secondary PH. Patients with a decreased DLCO below
60% of their predicted value had higher mean concentrations of MMP-
7 (5.68 ng/ml) than patients with a DLCO level above 75% (3.80 ng/ml)
(p¼0.006). There was no significant difference for other organ
manifestations, e.g. oesophagus, kidney, musculoskeletal system,
digital ulcerations and sicca-syndrome.
Conclusions: These results indicate the correlation between high
MMP-7 levels and the more progressive course of fibrosis. Further
analyses seem to be interesting and important, whether MMP-7
activity is directly involved in the pathophysiology of this disease and
whether it naturally reflects tissue remodelling.
Disclosure statement: The authors have declared no conflicts of
interest.
233. ROLE OF ET-1 AND GM-CSF ON THE
DIFFERENTIATION POTENTIAL OF MONOCYTES IN
SYSTEMIC SCLEROSIS
Nadine Binai1, Thomas Huegle2 and Jaap van Laar1
1Musculoskeletal Research Group, Newcastle University, Newcastle
upon Tyne, United Kingdom; 2Felix Platter-Spital, Universita¨t Basel,
Basel, Switzerland
Background: Systemic sclerosis (SSc) is a rare but potentially life
threatening connective tissue disease characterised by vasculopathy,
inflammation, the production of autoantibodies and excessive fibrosis
of skin and internal organs. Fibrosis is defined by an excess production
of extracellular matrix (ECM) molecules predominantly of type I
collagen. The main producers of collagen are myofibroblasts. These
cells are characterized by the expression of a-SMA.
Monocytes are the first cells that infiltrate inflamed or damaged
tissue and they bear a high differentiation potential. Furthermore,
in SSc it is suggested that monocytes are activated and play an
important role in disease onset and progression. We postulate that
monocytes can differentiate into myofibroblasts-like cells under the
influence of soluble factors such as endothelin-1, IL-4 and GM-CSF
which are elevated in SSc serum.
Methods: To study the effect of ET-1 as well as GM-CSF and IL-4, we
isolated monocytes from whole blood of healthy controls or SSc
patients by ficoll and positive selection with CD14 beads. Monocytes
were cultured in the presence of the above soluble factors cytokines
over 14 days. Expression of a-SMA and type I collagen was then
determined by Western blotting, qPCR and immunofluorescence.
Results: Monocytes from healthy individual and SSc patients
responded different to certain stimuli. In particular, we found that
differentiation of healthy monocytes into a-SMA expressing cells is
strictly dependent on GM-CSF. However, in patient monocytes ET-1
and IL-4 are also able to promote a-SMA expression but to a lesser
extend than GM-CSF. Furthermore, we observed that type I collagen
expression requires GM-GSF treatment but can be enhanced with
costimulation of ET-1.
Conclusions: These data suggest that monocytes can differentiate
into a myofibroblast-like phenotype and that SSc patient monocytes
require a less complex stimulation to do so. Understanding the role of
monocytes in fibrosis may contribute to the development of novel
therapies for systemic sclerosis.
Disclosure statement: The authors have declared no conflicts of
interest.
234. THE RELEVANCE OF THE EPITHELIAL-MESENCHYMAL
TRANSITION FOR SYSTEMIC SCLEROSIS
Xu Shiwen1, S. Sonnylal2, A. Tam1, H. Jones1, Richard Stratton1,
A. Leask3, J. Norman1, C. Denton1, B. de Crombrugghe2 and
D. Abraham1
1Rheumatology, Royal Free Hospital, London, United Kingdom;
2Genetics, UT M. D. Anderson Cancer, Houston, TX, USA; 3Oral
Biology, University of Western Ontario, London, ON, Canada
Background: Systemic sclerosis (SSc) is a disorder of systemic and
dermal fibrosis of uncertain etiology. Recently, we found that SSc
epidermis is abnormal, taking on an activated phenotype observed
during wound healing and tissue repair. Epithelial-fibroblast interac-
tions are important during wound repair and in fibrosis. Based on
studies from transgenic mice over-expressing CTGF, our in vivo data
suggested that CTGF expression in fibroblastic cells in the skin and
lungs not only causes extensive fibrosis and myofibroblast transfor-
mation, but also changes in the differentiation program of adjacent
epithelial cells, which directly contributes to fibrogenesis. Here, we
focus on epithelial-mesenchymal transition (EMT) fibrosis disease,
SSc.
Methods: Whole skin biopsy material from SSc and controls (both
n¼ 4) was immediately frozen in liquid nitrogen after excision.
Epidermal cell layer was dissected surgically from the frozen material.
The tissue processing and phospho-kinase screening was performed
by Kinexus (Vancouver, Canada). All experiments were performed with
MEFs prepared from embryos from at least three different litters in a
mixed 129Sv/J:c57BI/6 background. MEF were plated on 0.1%
gelatine coatedplates and grown in DMEMþ 10%FBS. Human
epithelial cells (A549) cultured with DMEM. Cells were stimulated
with TGFbeta1 after serum starvation. Fibrosis and epithelial markers
were examined using immunofluorescence staining and Western blot
analysis.
Results: Phosphorylation arrays were performed on the epidermal
tissue from SSc patients and healthy controls to identify signaling
pathways activated in SSc epidermis. A number of EMT-related
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proteins were found to have elevated phosphorylation states in SSc
tissues versus controls, including c-Met, Wee1 protein-tyrosine kinase,
STAT3, Integrin-linked protein-serine kinase 1(p< 0.05). Further in vitro
studies, A549 exposed to TGFbeta develop a fibroblast morphology
and molecular markers associated with EMT (snail and CTGF). CTGF-
specific siRNA dose-dependently suppresses TGFbeta-induced snail
and CTGF protein expression towards basal levels in A549 cells.
Col1a2-CTGF-transgenic MEFs expressed epithelial marks, E-cad-
herin, b-catenin. The transcription factors Sox9 and snail are master
regulators of EMT. The transgenic MEFs showed significantly higher
expression levels for matrix genes and proteins that include typeI
Collagen, Fibronectin. Increased expression of SMA and CTGF
correlate with high levels of collagen expression.
Conclusions: In this study we show that phosphorylation array
analysis revealed induction of EMT protein kinase signaling in SSc
epidermis. Important growth factor, TGFbeta, promotes and triggers
epithelial cells EMT. Col1a2-CTGF-transgenic MEFs from transgenic
mice express both epithelial and mesenchymal markers. We propose
that in SSc, epidermal cells are in a persistently activated state and are
able to promote EMT which contributed fibrosis.
Disclosure statement: The authors have declared no conflicts of
interest.
235. ELEVATION OF N-TERMINAL PRO-BNP IN CLINICALLY
SIGNIFICANT SCLERODERMA HEART INVOLVEMENT
Cecilia B. Chighizola1,2, Pier Luigi Meroni2, Gerry Coghlan1,
Chris Denton1 and Voon Ong1
1Rheumatology, Royal Free Hospital, London, United Kingdom;
2Internal Medicine, University of Milan, Milan, Italy
Background: Cardiac involvement is common in Systemic Sclerosis
(SSc) and is often clinically occult. It is recognised as a poor
prognostic factor contributing significantly to mortality. Early detection
of cardiac disease with non-invasive tools is therefore critical.
Aim of this study was to assess the role of N-TproBNP in a
retrospective cohort of SSc patients with heart involvement.
Methods: 19 SSc patients (13 dcSSc and 6 lcSSc, 13 female) with
cardiac involvement were enrolled. Cardiac involvement was defined
as haemodynamically significant arrhythmias, pericardial effusion or
congestive heart failure, requiring specific treatment. All patients had
normal pulmonary artery systolic pressure and none had serum
creatinine over 140mol/l. This group was compared with 19 age- and
sex-matched SSc patients without evidence of cardiac involvement or
pulmonary hypertension. Normal serum N-TproBNP levels were less
than 20 pmol/l. Associations between N-TproBNP and left ventricular
ejection fraction, Troponin-I, systolic and diastolic blood pressure,
lung function and mRSS were determined by Pearson’s correlation
coefficient. Univariate mortality analysis was performed with Kaplan-
Meier method, we compared survival curves with Log-rank test.
Unpaired t-test was used to compare N-TproBNP values between
subgroups with or without cardiac involvement. ROC curves were
drawn to identify N-TproBNP levels with optimal sensitivity and
specificity for diagnosis of SSc-related cardiac involvement.
N-TproBNP levels were compared at presentation of cardiac involve-
ment and at six month follow up using a paired t-test. Within the group
with cardiac involvement, high levels of N-TproBNP levels were
defined as above the median value of 219 pmol/l.
Results: Compared with those without cardiac involvement,
N-TproBNP was significantly increased in SSc patients with cardiac
involvement (meanSD 14.9 14.5 pmol/l versus 10432053 pmol/l
respectively, p¼0.037; 95%CI 67,1989). ROC curves of N-TproBNP
to predict the presence of heart involvement in SSc were drawn:
a sensitivity of 100% was achieved at a cut-off of 28 pg/mL, with
a specificity of 84% (95% CI 0.95-1). There was a progressive
reduction in N-TproBNP after the acute phase of cardiac involvement
(meanSD 301 330 pmol/l) during 6 months follow-up (meanSD
87 113 pmol/l; p¼0.048, 95%CI 2.8,425). Serum N-TproBNP
levels correlated negatively with left ventricular ejection fraction
(with logarithmic transformation of N-TproBNP values, R2¼0.52,
p¼0.001). However, there was no correlation between N-TproBNP
and systolic and diastolic BP, troponin-I, mRSS, FVC and DLCO. In
addition, higher levels of N-TproBNP did not predict survival within the
two groups of patients with cardiac involvement.
Conclusions: These data suggest that N-TproBNP may be a
surrogate marker for cardiac involvement in SSc. Further studies are
required to evaluate the utility of N-TproBNP levels for cardiac
assessment in SSc patients.
Disclosure statement: The authors have declared no conflicts of
interest.
236. IGG FROM SYSTEMIC SCLEROSIS PATIENTS
PROMOTE IL-1a RELEASE FROM HUMAN KERATINOCYTES
Florence Newton1, Xu Shiwen1, Chris Denton1, David Abraham1 and
Richard Stratton1
1Rheumatology, Royal Free Hospital, London, United Kingdom
Background: Recently we found that the epidermis in systemic
sclerosis (SSc) has an abnormal wound healing phenotype, and that
epidermal cells from SSc patients promote fibroblast activation and
induce CTGF in fibroblasts. We propose that activation of the
epidermal keratinocytes is an important early event contributing to
the fibrosis seen. One possibility is that changes in the epidermis are
being initiated by an autoimmune process. We measured binding of
SSc patients’ IgG to cultured human keratinocytes, and determined
whether SSc patients’ IgG promote keratinocyte activation in tissue
culture.
Methods: Anti-keratinocyte antibody titres were determined for SSc
patients sera (30 limited subset, 30 diffuse subsets) and sera from
healthy control individuals (n¼ 30) using fixed normal human kerati-
nocytes as target antigen. Binding was assessed using secondary
HRP-labelled anti-human IgG. SSc and control IgG were affinity
purified from plasma by protein A column. Normal human keratino-
cytes were cultured under serum free conditions and then exposed to
SSc and healthy control IgG (both n¼3)(0, 10, 100mg/ml).
Keratinocyte activation was determined by measuring levels of IL-
1alpha in cell layer and media before and after exposure to IgG for 24
hours. Additional time course experiments were performed to
determine the kinetics of IL-1a release. Additional studies using
immunofluorescence were performed to determine binding of SSc IgG
to cultured keratinocytes, and to detect IgG in sections of SSc and
control epidermis.
Results: Anti-keratinocyte antibody titres were in increased in both
limited SSc and diffuse SSc sera compared to controls (Table 1). There
was a non significant trend toward increased IL-1a release by SSc IgG
10ug/ml at 24 hours (untreated keratinocyte cell layer 47.6 pg/ml,
media 1.8 pg/ml, control IgG treated cell layer 26.2 pg/ml, media
7.5 pg/ml, SSc IgG treated cell layer 33.7 pg/ml, media 27.9 pg/ml
(p not significant)). A time course of IL-1a release following treatment
with SSc and control IgG (10mg/ml) was determined by treating
keratinocytes in 6 well plates and removing media and lysing cell layer
at various timepoints. SSc IgG lead to a rapidly evoked and biphasic
induction of IL-1a release. Positive immunfluorescence for IgG was
seen in 2 out of 6 recent onset SSc epidermal biopsies.
Conclusions: Cellular injury or activation by autoantibodies in
systemic sclerosis (SSc) remains a controversial area, with variation
in findings between centres, and a number of potential mechanisms
shown. Our idea, supported by the above results, is that SSc
antibodies induce innate responses in resident cells including
keratinocytes. Possible mechanisms include induction of TLR signal-
ling, or carriage of SSc autoantigens into target cells.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1.
control sera
(n¼ 30)
limited SSc sera
(n¼ 30)
diffuse SSc sera
(n¼ 30)
Anti-keratinocye
ELISA (%) (median,
interquartile range).
6.11 (0-28.7) 23.8 (5.2-43.4) 18.8 (9.8-36.0)
p (Mann-Whitney test) p< 0.026 p< 0.030
237. AN EXPLORATION OF PULMONARY VASCULAR VEGF
SIGNALLING IN A TGFb-DEPENDENT MOUSE MODEL
OF SYSTEMIC SCLEROSIS
Emma C. Derrett-Smith1, Audrey Dooley1, Reshma Baliga2,
Adrian Hobbs2, Raymond MacAllister2, David Abraham1 and
Chris Denton1
1Centre for Rheumatology and Connective Tissue Diseases,
Royal Free Campus, UCL Medical School, London, United Kingdom;
2Centre for Cardiovascular Pharmacology, UCL, London,
United Kingdom
Background: Vascular complications of systemic sclerosis (SSc) are
a major cause of mortality and morbidity. A role for altered VEGF
signalling in PAH-SSc is supported by data that correlate circulating
VEGF with mPAP at diagnosis. High circulating VEGF levels may be a
marker of repair in response to vascular injury. We have therefore
examined VEGF signalling in a TGFb-dependent mouse model of SSc
with evidence of a constitutive pulmonary vasculopathy.
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Methods: The transgenic mouse strain TbRIIk-fib expresses a
kinase-deficient type II TGFb receptor driven by a fibroblast-specific
promoter leading to balanced ligand-dependent upregulation of TGFb
signalling. Pulmonary vasculopathy was confirmed by histological
assessment of vessel architecture, isolated organ bath and in vivo
haemodynamic studies performed on adult male transgenic and
littermate wildtype animals (n¼8 in each group). Biochemical analysis
of the VEGF and endothelin axes were performed assessing RNA by
quantitative PCR and protein by Western blotting using cultured aortic
and pulmonary artery smooth muscle cells, and by immunostaining of
tissue sections. Results were compared to the same cells cultured
under hypoxic conditions. A pharmacological inhibitor of VEGF
signalling was then administered to investigate effects of perturbed
VEGF signalling in vivo.
Results: Within the pulmonary arterial circulation, transgenic vessel
wall thickness was increased, particularly in smaller vessels (30-60m
diameter) due to hypertrophy of the smooth muscle layer (mean
wildtype vessel thickness:circumference ratio 0.660.02, mean
transgenic 0.880.04, p< 0.05). Pulmonary arterial ring responses
to direct and receptor-mediated contractile stimuli were reduced in the
transgenic animals (in response to endothelin contraction at 10-5M
wildtype 1.10 mN0.02, transgenic 0.620.12, p<0.05) and right
ventricular pressures were elevated in transgenic animals (wildtype
mean 29 mmHg 4, transgenic mean 37 mmHg 3). Explanted
transgenic vascular smooth muscle cells showed upregulation of
TGFb responsive genes including VEGF and VEGFR1 which were
further upregulated in the pulmonary arterial circulation (PASMC) when
compared to aortic smooth muscle cells (AoSMC) from the same
animals, particularly when cultured in a hypoxic environment.
Administration of SU5416, a VEGF receptor inhibitor, resulted in
endothelial proliferation within the pulmonary circulation.
Conclusions: The pulmonary vascular phenotype of this transgenic
mouse model appears to replicate key histological and patho-
physiological features of human SSc, and supports a potential role
for perturbed TGFb and VEGF activity in the pulmonary circulation in
this model. Administration of a VEGFR inhibitor in this model may more
accurately replicate the pulmonary vasculopathy of human SSc.
Disclosure statement: The authors have declared no conflicts of
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238. ANALYSIS OF POLYMORPHISMS IN THE STAT4, IRF5
AND BANK1 GENES IN UK PATIENTS WITH SYSTEMIC
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United Kingdom; 3The National Pulmonary Hypertension Unit,
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Background: Scleroderma or systemic sclerosis (SSc) is a complex
genetic disease. Recent studies, have found consistent associations
between polymorphisms in STAT4, IRF5 and BANK1 with SSc, both at
a susceptibility level and with specific clinical aspects of the disease.
The aim of the study was to investigate whether the previously
reported association of polymorphisms in STAT4, IRF5 and BANK1
genes in patients with SSc, is also apparent in an extended group of
UK Caucasian SSc patients.
Methods: Patients with SSc (436) and 245 healthy controls were
screened for polymorphisms in STAT4 (rs1188934, rs7574865), IRF5
(rs2004640) and BANK1 (rs10516487) genes. All patients and controls
were UK Caucasoid. Patients were grouped according autoantibody
status in 3 mutually exclusive groups: anti-topoisomerase1 (ATA),
anticentromere (ACA) and antiRNA-polymerase (ARA). We also divided
the groups according organ involvement; lung fibrosis (LF) (assessed
by HRCT and lung function test) and pulmonary arterial hypertension
(PAH) (defined as an elevation in the mean pulmonary artery pressure
>25 mmHg with normal pulmonary capillary wedge pressure
(< 15 mmHg) on right heart catheterisation). Genotyping was
performed by the KASPar system (allele specific PCR, KBiosciences,
UK). Statistical analysis: 3x2 tables and Chi-square analysis was used
to compare the distribution of the polymorphism between the groups
of patients and controls. P<0.05 was considered statistically
significant.
Results: Of the SSc patients, 285 (65.4%) were limited cutaneous
(lcSSc) and 151 (34.6%) were diffuse cutaneous (dcSSc). There were
182 (41.7%) patients with LF and 75 (17.2%) with PAH. One hundred
and five patients (24%) were positive for ATA, 143 (32.8%) for ACA and
93 (21.3%) ARA. We found a significant difference (p¼0.004) in the
genotype distribution of the IRF5 polymorphism between the control
and SSc groups, while no association was observed between the SSc
group as a whole and STAT4 or BANK1. There was a difference in the
genotype distribution of the IRF5 polymorphism in the lcSSc group
when compared with controls (p¼ 0.004). There was a significant
variation in the allele distribution of the IRF5 polymorphism in patients
with lung fibrosis (p¼0.01) and with ATA (p¼ 0.01) when compared
with controls. Conversely, BANK1 was associated with PAH
(p¼0.0005), but not with ACA. We also detected an association of
both STAT4 polymorphisms with the presence of ACA (p¼0.01).
Conclusions: We confirm several of the reported associations of
the STAT4, IRF5 and BANK1 polymorphisms with SSc in the UK
Caucasian population. These genes have been described to have a
role in immune regulation, and have been found to be associated with
other autoimmune diseases such as rheumatoid arthritis and systemic
lupus erythematosus, suggesting a common genetic pathway for
autoimmunity. Our findings add further support for the role of genetic
factors in the autoimmune component of SSc.
Disclosure statement: The authors have declared no conflicts of
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Background: Systemic sclerosis (SSc) has a complex genetic
background and is likely to involve several genes from different
chromosomes. SSc is characterized by vascular alterations, auto-
immunity and fibrosis. We have previously shown that the transcription
factor NKX2-5, (chromosome 5q34), activates the collagen1a2
enhancer, stimulating collagen type I production in blood vessels. In
addition we have shown abnormal expression of NKX2-5 in human
pulmonary vessels of SSc patients with pulmonary arterial hyperten-
sion. Furthermore, NKX2-5 polymorphism has been recently shown to
be associated with systemic lupus erythematosus, another auto-
immune disease with vascular complications. We therefore considered
NKX2-5 to be a good candidate gene for association studies in SSc.
The aim of the study was to determine the genotype frequency of
selected NKX2-5 polymorphisms in the SSc and control groups, and to
ascertain the association of NKX2-5 polymorphisms with SSc and with
its specific clinical and serological subgroups.
Methods: We screened 517 UK SSc patients and 378 healthy
unrelated controls for 10 polymorphisms in the NKX2-5 gene region
using a sequence-specific primer PCR (SSP-PCR). The polymorph-
isms studied were: rs6891790, rs1006225, rs6882776, rs3095870,
rs12188595, rs3729937, rs17052019, rs11955407, rs3729938 and
rs703752. All patients and controls were Caucasoid. Statistical
analysis: logistic regression analyses were used to compare the
distribution of NKX2-5 polymorphism alleles between the study
groups. p>0.05 was considered statistically significant.
Results: The SSc patients group (total 517; 341 limited cutaneous and
175 diffuse cutaneous) included 122 anti-topoisomerase1 antibody
positive (ATA) individuals, 153 anticentromere antibody positive (ACA)
individuals, and 222 individuals with fibrosing alveolitis.
All the genotypes tested were in Hardy Weinberg equilibrium.
No significant difference was found in genotype, allele frequency or
haplotypes for any of the investigated polymorphisms in NKX2-5,
when SSc group as a whole and control subjects were compared.
However, there was a significant association between the rare T allele
of both rs3095870 and rs703752 polymorphisms in patients with ATA
compared to SSc without this antibody (p¼0.04 odds ratio 1.35
confidence interval 95% 1.00 - 1.83, and p¼0.03 odds ratio 1.39
confidence interval 95% 1.02-1.88).
Conclusions: 10 polymorphisms in the region of the NKX2-5 gene
were genotyped in groups of SSc patients and controls. The frequency
of the rare T allele of the rs3095870 and rs703752 SNPs were
associated with ATA subgroup of SSc patients. These variants are
located in the promoter and the 3’UTR regions of NKX2-5, respec-
tively. These areas are known to play a key role in the regulation of
a gene expression and mRNA stability, suggesting a functional role
of the SNPs in the NKX2-5 expression.
Disclosure statement: The authors have declared no conflicts of
interest.
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240. AUTO-ANTIBODY STATUS AND DISEASE
MANIFESTATIONS OF PATIENTS WITH SCLERODERMA
ASSOCIATED DIGITAL ULCERS: DATA FROM THE
DUO REGISTRY
Chris Denton1, Loic Guillevin2, Thomas Krieg3, Barbara Schwierin4,
Daniel Rosenberg5, Mariabeth Silkey4 and Marco Matucci-Cerinic6
1Centre for Rheumatology and Connective Tissue Diseases, Royal
Free Hospital, London, United Kingdom; 2Department of Internal
Medicine, Paris Descartes University, Paris, France; 3Department of
Dermatology, University of Cologne, Cologne, Germany; 4Global
Medical Science, Actelion Pharmaceuticals, Allschwil, Switzerland;
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Background: Digital ulcers (DU) are a frequent, persistent and
debilitating manifestation of systemic sclerosis (SSc). The DUO
Registry is a European, prospective, multicentre, observational
cohort study of patients with SSc associated DU; 271 centres (9 in
the UK) are involved. This registry has potential to explore the
relationship between DU disease and auto-antibody status and
whether specific auto-antibody subsets or DU are more prone to
occur in association with particular disease manifestations. Here, we
describe the antibody profile, disease duration and organ-based
manifestations of patients in the DUO Registry.
Methods: Patients undergo clinical assessments and receive standard
medical care as determined by the patient’s physician. All consenting
consecutive SSc patients with ongoing DU irrespective of treatment
regimen, are enrolled. Data collected since April 2008 includes
demographics, auto-antibody status, disease history, and organ
manifestations.
Results: Up to May 19, 2010, 1966 patients have been enrolled
(82.3% female, meanSD age 54.214.1 yrs. 51.1% of patients
were classified with limited SSc and 38.0% with diffuse SSc. Almost all
(95.6%) patients tested were positive for ANA; 45.6% for anti-Scl 70
antibodies, 43.5% for anti-centromere antibodies (ACA) and 11.2% for
anti-RNA polymerase III. Few patients had a combination of these
antibodies (anti-Scl 70 & ACA: n¼53, 2.7%; Anti-Scl 70 Ab & RNA
polymerase III: n¼35, 1.8%). Compared with ACA-positive patients,
anti-Scl 70 positive patients had shorter time periods from onset
of Raynaud’s phenomenon (RP) to first DU (anti-Scl 70: 6.0 [95%
CI 5.3-6.6] yrs; ACA: 8.2 [95% CI 7.2-9.1] years) and from first non-RP
manifestation to first DU (anti-Scl 70: 3.1 [95% CI 2.7-3.4] yrs; ACA: 4.2
[95% CI 3.5-4.8] yrs). Lung fibrosis was most common (62.8%) in the
anti-Scl 70 subset. The frequency of kidney, heart and GI manifesta-
tions appeared to be similar across antibody subsets (Table 1).
Conclusions: Across the antibody subsets, patients positive for anti-
Scl 70 had the highest frequency of lung fibrosis, and the most rapid
disease evolution as reflected by the lag time from RP or first non-RP
manifestation to first DU. Regardless of SSc type, our data suggest
ongoing DU disease in patients with anti-scl70, which itself is a marker
of poor outcome in SSc, is associated with the presence of organ
involvement.
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241. LOSS OF PTEN EXPRESSION IN SKIN FIBROBLASTS
CONTRIBUTES TO FIBROSIS IN SCLERODERMA
Sunil Parapuram1, Xu Shi-wen2, Christopher Denton2,
David Abraham2 and Andrew Leask1
1Dentistry, University of Western Ontario, London, ON, Canada;
2Rheumatology, University College London, London,
United Kingdom
Background: Skin fibrosis, the increased collagen deposition and
contraction by fibroblasts resident within connective tissue, is a princi-
pal feature of scleroderma and is believed to result from a hyperactive
tissue repair program. The protein phosphatase and tensin homolog
(PTEN) suppresses various activities of cell including migration,
contractility, survival and collagen production and thus may modulate
tissue repair. We investigate whether loss of PTEN expression in skin
fibroblasts is sufficient to result in fibrosis.
Methods: Skin fibroblasts were isolated from clincally affected areas
of patients with early onset diffuse systemic sclerosis (scleroderma).
Age- site- and sex- matched skin fibroblasts from healthy individuals
served as controls. Western blot analysis was used to detect PTEN
expression in normal and scleroderma fibroblasts. To assess whether
loss of PTEN expression was sufficient for fibrogenesis in vivo, mice
homozygous for a loxP-Pten allele and hemizygous for a tamoxifen-
dependent cre recombinase expressed under the control of a
fibroblast-specific type I collagen promoter were used, and either
treated with tamoxifen (to delete Pten specifically in adult fibroblasts)
or corn oil (vehicle; to generate control mice). Fibrosis in these mice
was assessed histologically and by determining collagen levels using a
hydroxyproline/proline assay. Western blot analysis was used to test
whether adenoviral-delivered overexpression of PTEN rescued the
fibrotic phenotype of scleroderma fibroblasts.
Results: PTEN protein expression was markedly decreased in
scleroderma dermal fibroblasts (N¼6; p< 0.05). Mice deleted for
Pten in fibroblasts (Pten -/-) possessed increased (a) thickness of the
dermis (Ptenþ /þ: 16857 mm, Pten-/- : 372112 mm, p<0.04) and
(b) collagen deposition (hydroxyproline content: Ptenþ/þ: 3.71.0,
Pten-/-: 4.90.8 g/100 g tissue p<0.03) compared to controls (Pten
þ/þ). Compared to control Ptenþ/þ dermal fibroblasts, cultured
Pten-/- dermal fibroblasts produced elevated levels of the phosphory-
lated form of Akt as well as type I collagen (N¼3; p<0.05); collagen
overexpression in Pten-/- dermal fibroblasts was suppressed by
inhibitors of PI3K/Akt signaling (LY294002 and wortmannin) (N¼3;
p<0.05). Reintroduction of PTEN into scleroderma fibroblasts
rescued the overproduction of type I collagen by this cell type
(N¼3; p< 0.05).
Conclusions: Loss of PTEN expression in fibroblasts is sufficient to
create a fibrotic phenotype and hence could be a major factor in the
development of fibrosis in scleroderma. Thus, PTEN agonists could
be an important novel anti-fibrotic treatment for the skin fibrosis
in scleroderma.
Disclosure statement: The authors have declared no conflicts of
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242. SERUM LEVELS OF MMP7 AND MMP9 IN SYSTEMIC
SCLEROSIS: CLINICAL ASSOCIATIONS AND POTENTIAL
AS DISEASE BIOMARKERS
Svetlana Nihtyanova1, Bahja Ahmed Abdi1, Korsa Khan1,
David Abraham1 and Chris Denton1
1Centre for Rheumatology and Connective Tissue Diseases,
Royal Free Hospital, London, United Kingdom
Background: It has been shown that matrix metalloproteinase (MMP)
9 levels are increased in subjects with systemic sclerosis (SSc)
compared to controls and that they correlate positively with modified
Rodnan skin score (mRss). Raised MMP7 levels have been observed
in patients with idiopathic pulmonary fibrosis (PF).
Methods: Using a commercially available ELISA we measured MMP7
and MMP9 levels in sera from patients with SSc and healthy controls,
looking for correlations with clinical presentation.
TABLE 1.
ANA Anti-Scl 70 ACA Anti-RNA Pol III Anti-U1 RNP Anti-U3 RNP
Diffuse SSc, n/N (%) 637/1654 (38.5) 451/683 (66.0) 81/618 (13.1) 34/77 (44.2) 29/102 (28.4) 11/38 (28.9)
Limited SSc, n/N (%) 839/1654 (50.7) 195/683 (28.6) 500/618 (80.9) 27/77 (35.1) 31/102 (30.4) 13/38 (34.2)
Overlap SSc/ Mixed
CTD, n/N (%)
120/1654 (7.3) 17/683 (2.5) 21/618 (3.4) 10/77 (13.0) 35/102 (34.3) 12/38 (31.6)
Other, n/N (%) 58/1654 (3.5) 20/683 (2.9) 16/618 (2.6) 6/77 (7.8) 7/102 (6.8) 2/38 (5.3)
Lung fibrosis, % (95% CI) 42.8 (40.4, 45.2) 62.8 (59.1, 66.4) 45.5 (34.1, 57.2) 22.2 (19.0, 25.7) 43.1 (33.4, 53.3) 47.4 (31.0, 64.2)
Pulmonary arterial
hypertension, % (95% CI)
16.0 (14.3, 17.9) 16.3 (13.6, 19.3) 16.9 (9.31, 27.1) 17.4 (14.5, 20.6) 16.7 (10.0, 25.3) 26.3 (13.4, 43.1)
Kidney, % (95% CI) 5.0 (4.04, 6.21) 5.7 (4.06, 7.67) 7.8 (2.91, 16.2) 3.7 (2.36, 5.51) 8.8 (4.11, 16.1) 13.2 (4.41, 28.1)
Gastrointestinal tract, %
(95% CI)
58.5 (56.1, 60.9) 60.2 (56.4, 63.9) 59.7 (47.9, 70.8) 57.8 (53.8, 61.7) 55.9 (45.7, 65.7) 42.1 (26.3, 59.2)
Heart, % (95% CI) 10.9 (9.47, 12.5) 12.4 (9.99, 15.0) 9.1 (3.73, 17.8) 6.4 (4.64, 8.67) 11.8 (6.23, 19.6) 13.2 (4.41, 28.1)
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Results: Sera from 43 consecutive limited cutaneous (lc) SSc
subjects, 44 early (<3 years from disease onset) diffuse cutaneous
(dc) SSc patients and 20 age, gender and ethnicity matched healthy
controls were analysed. There were no differences between lcSSc and
dcSSc patients in terms of gender or ethnicity, age at disease onset or
sample collection. As expected the lcSSc subjects more often had
overlap syndromes compared to the dcSSc ones (30% v 11%,
p<0.001), and had higher frequency of anti-centromere antibodies
(49% v 2%, p<0.001), while anti-RNA polymerase III antibodies were
found only in the dcSSc cohort (32% v 0%, p<0.001). The meanSD
disease duration at sample collection was significantly longer for the
lcSSc cohort (13283 months) compared to 2212 for dcSSc
cohort. There were no differences between the two subsets in
frequency of clinically significant internal organ disease. MMP7
levels varied between 1.1 and 84.5 ng/mL (meanSD 8.8 8.5,
median 6.7 ng/mL) while MMP9 levels were measured between 54
and 5405 ng/mL (meanSD 651.9562, median 548.6 ng/mL). There
was no correlation between MMP7 and MMP9 levels.
We found no gender or ethnicity differences in the levels of MMP7
and MMP9. Compared to healthy controls SSc patients had altered
levels of both MMP7 and MMP9 - mean MMP7 level was 10.2 ng/mL
for dcSSc, 8.9 ng/mL for lcSSc and 4.6 ng/mL for control groups
(p<0.001) while mean MMP9 level was 892 ng/mL for dcSSc, 460.8 ng/
mL for lcSSc and 607.2 ng/mL for controls (p< 0.001). The only
significant association with autoantibodies we observed was for anti-
topoisomerase I antibody (ATA) positive patients who had higher
MMP7 levels (mean 14.3 ng/mL) compared to ATA negative subjects
(8.23 ng/mL), p¼0.049. MMP7 levels were also higher in subjects with
clinically significant (cs) PF (13.8 ng/mL) compared to those without
(8.13 ng/mL, p¼ 0.017) and in subjects who developed renal crisis
(16.5 ng/mL) compared to those who did not (8.8 ng/mL, p¼0.016).
There was no association of MMP7 and MMP9 levels with pulmonary
hypertension, cardiac scleroderma or severe digital vasculopathy. We
also found no correlation between mRss and MMP7 or MMP9 levels.
Conclusions: Both MMP7 and MMP9 levels were higher in dcSSc
subjects compared to lcSSc subjects or controls. Higher MMP7 levels
were also associated with ATA positivity, development of csPF and
SRC. Both MMP7 and MMP9 may have potential as biomarkers in SSc
and further study is warranted.
Disclosure statement: The authors have declared no conflicts of
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243. ELEVATED IL-6 LEVELS ASSOCIATE WITH POOR
CLINICAL OUTCOME AND MAY PROMOTE FIBROSIS
IN EARLY dcSSc
Korsa Khan1, Chris Denton1, Shiwen Xu1 and Voon Ong1
1Centre for Rheumatology and Connective Tissue Diseases, London,
United Kingdom
Background: We previously showed that thrombocytosis may identify
a subgroup of diffuse SSc with increased IL-6 and high modified
Rodnan skin score (mRSS). We assessed the predictive value of high
IL-6 in these patients and its role in driving fibrosis in SSc.
Methods: IL-6 levels were assessed with immunohistochemistry and
Western blot analysis. Skin biopsies from patients with early dcSSc
and thrombocytosis(n¼ 10,mean platelet:472x109/L,disease duration,
MeanSEM:35 9.5 months),established dcSSc(n¼8,mean plate-
let:293x109/L, disease duration:12822) and controls(n¼ 12) were
used. IL-6 levels were measured in the supernatant from cultured SSc
fibroblasts and the effect of anti-IL6 receptor antibody on collagen
production was examined in normal fibroblasts stimulated with IL-6.
To investigate the link between IL-6 levels and clinical outcome
serum IL-6(in pg/ml) from 39 patients with dcSSc (74% female) was
quantified by ELISA. The dcSSc cases were categorised into high
IL-6(10 pg/ml) and low IL-6 cohorts. Association between IL-6 levels
and mRSS at 36months from disease onset was determined by
Pearson’s correlation. Mean difference of mRSS between the two
cohorts of IL-6 levels over the 36-month period was compared by
Student t-test. Difference in survival between cohorts was examined
using Kaplan-Meier methods.
Results: There was greater dermal IL-6 expression in patients with
early dcSSc than other subgroups. Strong immunostaining for IL-6
was associated with dermal fibroblasts, vascular structures and
mononuclear inflammatory infiltrate in 80% of patients with early
dcSSc. Moderate vascular expression for IL-6 was observed in 33% of
healthy controls. Similar expression pattern was observed in 25%
patients with established dcSSc with weak staining for IL-6 in dermal
fibroblasts and inflammatory infiltrates.
IL-6 was elevated in the supernatant from cultured SSc fibroblasts
(n¼ 3) by 17-fold (Densitometric Image Unit, DIU p<0.05). In addition,
collagen production was upregulated by 7-fold in SSc fibroblasts and
similar induction by recombinant IL-6(20 ng/ml) was observed in
normal fibroblasts (17.94þ3.41 vs 2.18þ 1.85 DIU control, p<0.05).
This was partially abrogated with neutralising antibody against IL-6
receptor (4.26þ2.07 DIU, p<0.05).
Serum IL-6 level at presentation positively correlated with mRSS
at 36 months follow-up in a subgroup of dcSSc cases (r¼0.81,
p<0.01, n¼16). There was a significant difference in mean mRSS
between the two groups with differential IL-6 expression (10.9, 95%
Confidence interval, 3.8, 18.2, p<0.01). Kaplan-Meier analysis
showed that the 5-year survival was 93% and 81% in the group with
low and high IL-6 levels respectively (p¼0.02, log rank test).
Conclusions: This data confirms upregulation of IL-6 in some cases of
early dcSSc and support the potential role of IL-6 as a surrogate
marker for clinical outcome in SSc. Our study also suggests that IL-6
may a logical target for therapy in this subset of patients.
Disclosure statement: The authors have declared no conflicts of
interest.
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PHYSICAL EXAMINATION AS GOLD STANDARD
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Background: Sacroiliac joints (SJ) involvement is a distinctive and
charasteristic feature of Spondyloarthritis (SpA) and x-ray is the test
routinely used to make a diagnosis. However, x-ray reveals late
structural damage but cannot detect active inflammation. The
objective of this study was to assess the validity of Doppler ultrasound
in SJ.
Methods: Prospective blinded and controlled study of SJ, in which
three populations were compared. We studied 106 consecutive cases,
who were divided into three groups: a) 53 patients diagnosed with
SpA who had inflammatory lumbar and gluteal pain assessed by a
rheumatologist; b) 26 patients diagnosed with SpA who didn’t have
SJ tenderness and had normal physical examination; c) control group
of 27 subjects (healthy subjetcs or with mechanical lumbar pain).
All patients included that were diagnosed with SpA met almost the
European Spondyloarthropathy Study Group (ESSG) classification
criteria. Physical examination of the SJ included: sacral sulcus
tenderness, iliac gapping, iliac compression, midline sacral thrust
test, Gaenslen’s test, and Patrick s test were used as gold standard.
Both SJ were examined with Doppler ultrasound (General Electric
Logiq 9, Wauwatosa WI, USA) fitted with a 9-14 Mhz lineal probe. The
ultrasonographer was blinded to clinical data.
Doppler in SJ was assessed as positive when both Doppler colour
and resistance index (RI)<0.75 within the SJ area were present.
Statistical analysis was performed estimating sensitivity and specificity
against gold standard. The Kappa correlation coefficient was used for
reliability study.
Results: 106 cases (53 female, 55 male; mean age 36 10 years) were
studied. There were no statistical differences between groups related
to age or sex. Physical examination of SJ was positive in 38 patients
(59 sacroiliac joints). US detected Doppler signal within SJ in 37
patients (58 SJ): 33 of them were symptomatic SpA (52 SJ), one of
them were asymptomatic SpA (1 SJ) and one was a healthy control (1
SJ). The accuracy of US when compared to clinical data as gold
standard at subject level in the overall group was: sensitivity of 68.6%
and specificity of 85.7%, positive predictive value of 70.5% and
negative predictive value of 84.5%. A positive likelihood ratio of 4.8, a
negative likelihood ratio of 0.36 and a kappa coefficient of 0.55 were
achieved.
Conclusions: Doppler US of SJ seems to be a valid method to detect
active SJ inflammation.
Disclosure statement: The authors have declared no conflicts of
interest.
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